The present study was aimed at the formulation and evaluation of Glimepiride 4 mg sustained release tablets to enhance therapeutic efficacy and improve patient compliance. Glimepiride, a third-generation sulfonylurea, is widely used in the treatment of Type 2 Diabetes Mellitus. Due to its short biological half-life and requirement for prolonged glycemic control, sustained release formulations were developed using hydrophilic polymers such as HPMC K100M and carbapol 934P. The SR- Tablets were prepared by wet granulation method and evaluated for pre-compression and post-compression parameters. And In-vitro dissolution studies were performed for 12 hours, and release kinetics were analyzed. The optimized formulation showed controlled drug release with good physicochemical properties, indicating suitability for sustained release therapy.
Dr. Vinod D. Usnale1*, Ms. Nila Priti Baswaraj1, Patel Kaif Altaf1, Palak Devi1, Pandhare Payal Sunil1, Murkute Vishwajeet Vilas1 (Thu,) studied this question.